Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 63

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 63
---
, may require that our compensation & people committee vary from its historic compensation practices or deviate from its general compensation philosophy under certain circumstances. For the purposes of informing 2025 compensation decisions, the compensation & people committee, with the advice of Aon, examined the peer group list and, with reference to market capitalization, therapeutic area, stage of development, number of employees and other key business metrics, approved the following 2025 peer group:

| ACADIA Pharmaceuticals Inc.    |     | Blueprint Medicines Corporation |     | Sage Therapeutics, Inc.        |
| Amicus Therapeutics, Inc.      |     | Crinetics Pharmaceuticals, Inc. |     | SpringWorks Therapeutics, Inc. |
| Apellis Pharmaceuticals, Inc.  |     | Intellia Therapeutics, Inc.*    |     | Travere Therapeutics, Inc.     |
| Arcus Biosciences, Inc.*       |     | Mirum Pharmaceuticals, Inc.     |     | Ultragenyx Pharmaceutical Inc. |
| Biocryst Pharmaceuticals, Inc. |     | Rhythm Pharmaceuticals, Inc.    |     |                                |
| *addition to 2025 peer group   |     |                                 |     |                                |

Our compensation & people committee made adjustments to our 2025 peer group to ensure it represented a group of biopharmaceutical companies that aligns with us in key measures based on our disease area focus, the current state of our commercialization efforts, and our development pipeline, focusing on companies with:

| • |     | approximately 200 to 1,500 employees; |

| • |     | a market capitalization between $800 million and $7.5 billion; |

| • |     | a late-stage clinical or early commercial-stage portfolio with a focus on rare diseases; and |

| • |     | annual revenue of less than $500 million. |

46

Specifically, Insmed Incorporated was removed from the 2025 peer group because the company’s market capitalization moved outside of our targeted range, and Mirati Therapeutics, Inc. was removed from the 2025 peer group due to the company having been acquired. Arcus Biosciences, Inc. and Intellia Therapeutics, Inc. were added to the 2025 peer group through an evaluation of potential peers meeting the above criteria. Executive Compensation Elements The primary elements of our executive compensation program are:

| • |     | base salary; |

| • |     | annual performance-based cash incentives